Literature DB >> 6304141

Practical protocol for cytomegalovirus isolation: use of MRC-5 cell monolayers incubated for 2 weeks.

W W Gregory, M A Menegus.   

Abstract

Isolation of cytomegalovirus (CMV) in tissue culture is presently the most reliable means of proving active CMV infection. To improve both the cost-effectiveness and clinical usefulness of procedures for the isolation of CMV from fresh clinical specimens, we analyzed results obtained with standard isolation procedures and compared them with results obtained under different conditions. Cell monolayers from commercial sources were inoculated with fresh specimens and then were observed for a cytopathic effect typical of CMV. Of 1,375 specimens submitted over a 12-month period, 6.4% were CMV positive in WI-38 monolayers within 28 days after inoculation. The mean day of CMV detection for 45 urine, 13 cervical-vaginal, and 5 saliva specimens was 6.7 +/- 3.1 (mean +/- standard deviation), 9.9 +/- 3.3, and 7.7 +/- 3.3 days, respectively, and 92% were positive within 14 days. When 1,058 subsequent specimens were inoculated in parallel onto WI-38 and MRC-5 cell monolayers, 8.7% were positive for CMV. MRC-5 cells were significantly more sensitive than WI-38 cells: 98% of all positive specimens appropriate for comparison were detected in MRC-5 cultures, but only 85% were detected in WI-38 cells. Although 1 specimen was positive in WI-38 cells only, 38% of all isolates were positive earlier (16 specimens) or only (10 specimens) in MRC-5 cultures. Based on these data, we have developed a practical 2-week protocol for CMV isolation from fresh clinical specimens that includes the use of MRC-5 cell monolayers incubated at 36 degrees C.

Entities:  

Mesh:

Year:  1983        PMID: 6304141      PMCID: PMC272701          DOI: 10.1128/jcm.17.4.605-609.1983

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  Propagation in tissue cultures of a cytopathogenic virus from human salivary gland virus (SGV) disease.

Authors:  M G SMITH
Journal:  Proc Soc Exp Biol Med       Date:  1956-06

2.  Comparison of WI-38, MRC-5, and IMR-90 cell strains for isolation of viruses from clinical specimens.

Authors:  H M Friedman; C Koropchak
Journal:  J Clin Microbiol       Date:  1978-04       Impact factor: 5.948

3.  Hayflick's Tragedy: The Rise and Fall of a Human Cell Line.

Authors:  N Wade
Journal:  Science       Date:  1976-04-09       Impact factor: 47.728

4.  Comparative study of diagnostic procedures for congenital cytomegalovirus infection.

Authors:  S Stagno; R F Pass; D W Reynolds; M A Moore; A J Nahmias; C A Alford
Journal:  Pediatrics       Date:  1980-02       Impact factor: 7.124

5.  Optimal method for recovery of cytomegalovirus from urine of renal transplant patients.

Authors:  M S Lee; H H Balfour
Journal:  Transplantation       Date:  1977-09       Impact factor: 4.939

6.  Characteristics of a human diploid cell designated MRC-5.

Authors:  J P Jacobs; C M Jones; J P Baille
Journal:  Nature       Date:  1970-07-11       Impact factor: 49.962

Review 7.  Epidemiology of chronic congenital and perinatal infections of man.

Authors:  C A Alford; R F Pass
Journal:  Clin Perinatol       Date:  1981-10       Impact factor: 3.430

8.  Epidemiology of cytomegalovirus infection after transplantation and immunosuppression.

Authors:  M Fiala; J E Payne; T V Berne; T C Moore; W Henle; J Z Montgomerie; S N Chatterjee; L B Guze
Journal:  J Infect Dis       Date:  1975-10       Impact factor: 5.226

Review 9.  Cytomegalovirus infections following renal transplantation.

Authors:  J Glenn
Journal:  Rev Infect Dis       Date:  1981 Nov-Dec

10.  Congenital cytomegalovirus infection: The relative importance of primary and recurrent maternal infection.

Authors:  S Stagno; R F Pass; M E Dworsky; R E Henderson; E G Moore; P D Walton; C A Alford
Journal:  N Engl J Med       Date:  1982-04-22       Impact factor: 91.245

View more
  14 in total

1.  Comparison of two leukocyte extraction methods for cytomegalovirus antigenemia assay.

Authors:  A García; J Niubò; M A Benítez; M Viqueira; J L Pérez
Journal:  J Clin Microbiol       Date:  1996-01       Impact factor: 5.948

2.  Rapid detection of cytomegalovirus in cell culture by indirect immunoperoxidase staining with monoclonal antibody to an early nuclear antigen.

Authors:  P D Swenson; M H Kaplan
Journal:  J Clin Microbiol       Date:  1985-05       Impact factor: 5.948

3.  [Selective detection of cytomegalovirus by in situ hybridization].

Authors:  U Cremer
Journal:  Z Rechtsmed       Date:  1988

4.  Comparison of two rapid culture methods for detection of cytomegalovirus in clinical specimens.

Authors:  P D Swenson; M H Kaplan
Journal:  J Clin Microbiol       Date:  1987-12       Impact factor: 5.948

5.  Comparative susceptibilities of strain MRC-5 human embryonic lung fibroblast cells and the Cooney strain of human fetal tonsil cells for isolation of rhinoviruses from clinical specimens.

Authors:  F C Geist; F G Hayden
Journal:  J Clin Microbiol       Date:  1985-09       Impact factor: 5.948

Review 6.  Cytomegalovirus infection in the gastrointestinal tract.

Authors:  R Chetty; D E Roskell
Journal:  J Clin Pathol       Date:  1994-11       Impact factor: 3.411

7.  Effect of incubation temperature on isolation of cytomegalovirus from fresh clinical specimens.

Authors:  W W Gregory; M A Menegus
Journal:  J Clin Microbiol       Date:  1983-10       Impact factor: 5.948

8.  In situ hybridization for the detection of cytomegalovirus (CMV) infection. Application of biotinylated CMV-DNA probes on paraffin-embedded specimens.

Authors:  T Löning; K Milde; H D Foss
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

9.  Evidence that neomycin inhibits human cytomegalovirus infection of fibroblasts.

Authors:  P E Lobert; D Hober; A S Delannoy; P Wattré
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

Review 10.  Viral infections in severely immunocompromised cancer patients.

Authors:  S M Devine; J R Wingard
Journal:  Support Care Cancer       Date:  1994-11       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.